




BMT CTN 0402

Sirolimus/Tacrolimus vs MTX/Tacrolimus to Prevent GVHD After HLA-identical Sibling PBSCT

Objective	Eligibility
<ul style="list-style-type: none"> ▪ Compare rate of Day 114 GVHD free survival between two study arms from time randomization using intent-to-treat analysis 	<ul style="list-style-type: none"> ▪ AML, MDS, CML, ALL ▪ 6/6 HLA matched sibling ▪ Age 2 - 60 years

TREATMENT SCHEMA



To view entire protocol, go to <http://www.bmtctn.net>
or the PDQ website at <http://cancer.gov/clinicaltrials/BMTCTN-0402>

This is a Phase III multi-center trial jointly sponsored by the NHLBI and NCI.